CHICAGO – Bristol-Myers Squibb Co.'s Opdivo (nivolumab), approved in March to treat certain patients with squamous non-small-cell lung cancer (NSCLC), can also provide significant benefit to patients with the more common nonsquamous form of NSCLC, especially those with tumors expressing high levels of tumor programmed death-ligand 1 (PD-L1), according to findings from the phase III CheckMate-057 study, presented Friday at the American Society of Clinical Oncology (ASCO) meeting.